What is the efficacy of combining Vyvanse (lisdexamfetamine) with bupropion for treating comorbid major depressive disorder and Attention Deficit Hyperactivity Disorder (ADHD), combined type?

From the Guidelines

The combination of Vyvanse (lisdexamfetamine) with bupropion can be effective for treating comorbid depression and ADHD combined type, though individual responses vary, as supported by the most recent evidence from 1 and 1. This combination addresses both conditions simultaneously: Vyvanse primarily targets ADHD symptoms through dopamine and norepinephrine modulation, while bupropion works as an antidepressant that also provides some benefit for ADHD symptoms through similar neurotransmitter pathways.

Key Considerations

• Typical dosing ranges from 20-70mg daily for Vyvanse and 150-450mg daily for bupropion (usually as XL or SR formulations).
• The medications should be started separately, often beginning with bupropion and adding Vyvanse after several weeks to assess individual responses and minimize side effects.
• Potential concerns include increased risk of seizures, elevated blood pressure, anxiety, insomnia, and appetite suppression, as noted in 1.

Monitoring and Adjustments

• Close monitoring is essential, especially during initiation and dose adjustments, as recommended by 1 and 1.
• This combination may be particularly useful for patients who haven't responded adequately to single-medication approaches, though alternatives should be considered if side effects become problematic or if the desired therapeutic effect isn't achieved.

Evidence Base

• The evidence from 1 and 1 suggests that bupropion is associated with a lower rate of sexual adverse events compared to other antidepressants, making it a potentially favorable choice for patients with comorbid depression and ADHD.
• However, the risk of seizures and other adverse effects should be carefully considered and monitored, as highlighted in 1.

From the Research

Combination of Vyvanse with Bupropion for Comorbid Depression and ADHD

• The effectiveness of combining Vyvanse (lisdexamfetamine) with bupropion for the treatment of comorbid depression and ADHD combined type is not directly addressed in the provided studies.
• However, study 2 compared the efficacy and tolerability of various medications, including amphetamines (which include Vyvanse) and bupropion, for the treatment of ADHD in children, adolescents, and adults.
• The study found that amphetamines were superior to placebo in reducing ADHD symptoms in both children and adults, while bupropion was also effective in adults.
• Study 3 discussed the use of bupropion in combination with serotonin reuptake inhibitors for the treatment of major depressive disorder (MDD), and found that the combination was effective in reversing antidepressant-associated sexual dysfunction and boosting antidepressant response.
• Study 4 investigated the efficacy and tolerability of combining antidepressants, including bupropion, for the treatment of acute depression, and found that combination therapy was associated with superior treatment outcomes compared to monotherapy.
• While these studies provide some insight into the potential effectiveness of combining Vyvanse with bupropion, they do not specifically address the treatment of comorbid depression and ADHD combined type.

Efficacy and Tolerability

• The provided studies suggest that both Vyvanse and bupropion are effective in treating ADHD and depression, respectively.
• However, the efficacy and tolerability of combining these medications for the treatment of comorbid depression and ADHD combined type are not well established.
• Study 2 found that amphetamines, which include Vyvanse, were associated with a higher risk of tolerability issues, such as increased heart rate and blood pressure, compared to other medications.
• Study 3 found that the combination of bupropion with serotonin reuptake inhibitors was generally well tolerated, but noted that additional randomized controlled studies are needed to fully assess the safety and efficacy of this combination.

Limitations

• The provided studies have several limitations, including the lack of direct evidence for the combination of Vyvanse with bupropion for the treatment of comorbid depression and ADHD combined type.
• Study 2 noted that the confidence of estimates varied from high to low or very low for some comparisons, and that the analysis was limited to a 12-week timepoint.
• Study 3 was limited to a review of existing literature, and noted that additional randomized controlled studies are needed to fully assess the safety and efficacy of combining bupropion with serotonin reuptake inhibitors.
• Study 4 found that the results were robust across prespecified secondary outcomes and sensitivity and subgroup analyses, but noted that there was indication of publication bias.